Rasheed Abdullah, Jabbour Salma K, Rosenberg Stephen, Patel Ajay, Goyal Sharad, Haffty Bruce G, Yue Ning J, Khan Alvin
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Department of Human Oncology, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin.
Pract Radiat Oncol. 2016 Sep-Oct;6(5):352-359. doi: 10.1016/j.prro.2015.12.006. Epub 2015 Dec 19.
Lung tumors move during respiration, complicating radiation therapy. The abdominal compression plate (ACP) is thought to reduce respiratory motion. This study quantifies ACP efficacy on respiratory-induced motion by using 4-dimensional computed tomography to evaluate volume and displacement changes of the heart, lungs, and tumor with and without ACP.
Lung cancer patients (n = 17) received 4-dimensional computed tomography simulations (10 computed tomography scans from 0% to 90% breathing phases) with and without ACP under maximally tolerated diaphragmatic pressure. Gross tumor volume (GTV), heart, and lungs were contoured in treatment planning software for each phase. Structures were exported for analysis. For each phase, with and without ACP, tumor and organ absolute centroid range of motion and volume were calculated.
ACP did not significantly affect GTV, heart, or lung motion on the sample as a whole, but instead demonstrated patient-specific results. ACP reduced GTV motion in 3 (17.6%; 3 upper lobe tumors) by 2.9 mm (P < .01), increased motion in 5 (29.4%; 3 upper lobe tumors, 1 middle lobe, 1 lower lobe) by 1.9 mm (P < .03), and did not significantly change 9. Of the 3 patients exhibiting significantly decreased GTV motion, GTV, heart, and lung range of motion was 7.4 mm, 11.8 mm, and 11.9 mm, respectively, without compression and 4.5 mm, 8.4 mm, and 10.9 mm, respectively, with compression. Averaged across the sample, ACP did not exhibit any axis-specific effect.
ACP efficacy was patient-specific, possibly because of pre-existing factors including chronic obstructive pulmonary disease severity, chest wall elasticity, tumor location, and patient comfort. Tumor lobe location does not predetermine compression efficacy; therefore, patients should be simulated with and without ACP, regardless of tumor location. GTV motion seems most important in determining suitability for compression. Alternative motion control should be considered in patients not benefited by compression. In patients who benefited, ACP may enhance tumor coverage while minimizing toxicity. Larger scale studies are necessary for definitive treatment recommendations.
肺部肿瘤在呼吸过程中会移动,这使放射治疗变得复杂。腹部压迫板(ACP)被认为可以减少呼吸运动。本研究通过使用四维计算机断层扫描来评估有和没有 ACP 时心脏、肺部和肿瘤的体积及位移变化,从而量化 ACP 对呼吸诱发运动的疗效。
肺癌患者(n = 17)在最大耐受膈肌压力下接受了有和没有 ACP 的四维计算机断层扫描模拟(从 0%到 90%呼吸阶段的 10 次计算机断层扫描)。在治疗计划软件中为每个阶段勾勒出大体肿瘤体积(GTV)、心脏和肺部的轮廓。将结构导出进行分析。对于每个阶段,计算有和没有 ACP 时肿瘤和器官绝对质心的运动范围及体积。
总体而言,ACP 对样本中的 GTV、心脏或肺部运动没有显著影响,而是呈现出个体特异性结果。ACP 使 3 例患者(17.6%;3 例上叶肿瘤)的 GTV 运动减少了 2.9 毫米(P <.01),使 5 例患者(29.4%;3 例上叶肿瘤、1 例中叶肿瘤、1 例下叶肿瘤)的运动增加了 1.9 毫米(P <.03),对 9 例患者没有显著影响。在 3 例 GTV 运动显著减少的患者中,无压迫时 GTV、心脏和肺部的运动范围分别为 7.4 毫米、11.8 毫米和 11.9 毫米,有压迫时分别为 4.5 毫米、8.4 毫米和 10.9 毫米。在整个样本中平均来看,ACP 没有表现出任何特定轴向上的影响。
ACP 的疗效具有个体特异性,可能是由于包括慢性阻塞性肺疾病严重程度、胸壁弹性、肿瘤位置和患者舒适度等预先存在的因素。肿瘤所在肺叶位置并不能预先决定压迫效果;因此,无论肿瘤位置如何,患者都应进行有和没有 ACP 的模拟。GTV 运动在确定是否适合压迫方面似乎最为重要。对于未从压迫中受益的患者,应考虑其他运动控制方法。对于受益的患者,ACP 可能会提高肿瘤覆盖率,同时将毒性降至最低。需要进行更大规模的研究以给出明确的治疗建议。